Formulation and Evaluation of Sustained Release Matrix Tablet of Captopril Article Swipe
Shilpa Gangurde*, Irshad Ahamad
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.17747600
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.17747600
Captopril, a potent angiotensin-converting enzyme (ACE) inhibitor, is widely prescribed for the management of hypertension and heart failure. However, its short biological half-life of about 1.5–2 hours and rapid systemic clearance necessitate multiple daily administrations to maintain therapeutic plasma concentrations. This frequent dosing results in poor patient adherence and fluctuating drug levels, ultimately reducing therapeutic effectiveness. Sustained release (SR) matrix tablets have emerged as a promising approach to overcome these limitations by providing controlled and prolonged drug release, maintaining steady plasma concentrations, and improving patient compliance. This review article provides a comprehensive account of the formulation and evaluation of sustained release matrix tablets of Captopril. It emphasizes formulation strategies employing hydrophilic and hydrophobic polymers such as hydroxypropyl methylcellulose (HPMC K4M and K15M), Carbopol 934, ethyl cellulose, and sodium alginate. The review details preformulation studies, formulation techniques like direct compression and wet granulation, evaluation parameters including physicochemical characterization, in vitro dissolution, and release kinetic studies. Mathematical modeling using zero-order, first-order, Higuchi, and Korsmeyer–Peppas equations is discussed to elucidate the mechanism of drug release. Optimized formulations demonstrated extended release profiles of up to 12–24 hours, following predominantly diffusion-controlled kinetics. Overall, sustained release matrix tablets of Captopril represent an effective strategy for enhancing antihypertensive therapy by reducing dosing frequency and improving bioavailability.
Related Topics
Concepts
Metadata
- Type
- article
- Landing Page
- https://doi.org/10.5281/zenodo.17747600
- OA Status
- green
- OpenAlex ID
- https://openalex.org/W7107951064
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W7107951064Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.5281/zenodo.17747600Digital Object Identifier
- Title
-
Formulation and Evaluation of Sustained Release Matrix Tablet of CaptoprilWork title
- Type
-
articleOpenAlex work type
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-28Full publication date if available
- Authors
-
Shilpa Gangurde*, Irshad AhamadList of authors in order
- Landing page
-
https://doi.org/10.5281/zenodo.17747600Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.5281/zenodo.17747600Direct OA link when available
- Concepts
-
Captopril, Dosing, Pharmacology, Drug, Matrix (chemical analysis), Chemistry, Dosage form, Biomedical engineering, Bioavailability, Immediate release, Human plasma, Controlled release, Plasma concentration, Medicine, Materials science, Pharmacokinetics, Chromatography, In vitro, PolymerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W7107951064 |
|---|---|
| doi | https://doi.org/10.5281/zenodo.17747600 |
| ids.doi | https://doi.org/10.5281/zenodo.17747600 |
| ids.openalex | https://openalex.org/W7107951064 |
| fwci | 0.0 |
| type | article |
| title | Formulation and Evaluation of Sustained Release Matrix Tablet of Captopril |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10256 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.7788326144218445 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3003 |
| topics[0].subfield.display_name | Pharmaceutical Science |
| topics[0].display_name | Drug Solubulity and Delivery Systems |
| topics[1].id | https://openalex.org/T10704 |
| topics[1].field.id | https://openalex.org/fields/30 |
| topics[1].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[1].score | 0.037080444395542145 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3003 |
| topics[1].subfield.display_name | Pharmaceutical Science |
| topics[1].display_name | Advancements in Transdermal Drug Delivery |
| topics[2].id | https://openalex.org/T11190 |
| topics[2].field.id | https://openalex.org/fields/22 |
| topics[2].field.display_name | Engineering |
| topics[2].score | 0.03309926390647888 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2204 |
| topics[2].subfield.display_name | Biomedical Engineering |
| topics[2].display_name | 3D Printing in Biomedical Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779479957 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8102431297302246 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q421119 |
| concepts[0].display_name | Captopril |
| concepts[1].id | https://openalex.org/C2777288759 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6100714802742004 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q4164182 |
| concepts[1].display_name | Dosing |
| concepts[2].id | https://openalex.org/C98274493 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5786994099617004 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[2].display_name | Pharmacology |
| concepts[3].id | https://openalex.org/C2780035454 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5417826771736145 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[3].display_name | Drug |
| concepts[4].id | https://openalex.org/C106487976 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5275700688362122 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q685816 |
| concepts[4].display_name | Matrix (chemical analysis) |
| concepts[5].id | https://openalex.org/C185592680 |
| concepts[5].level | 0 |
| concepts[5].score | 0.42619696259498596 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[5].display_name | Chemistry |
| concepts[6].id | https://openalex.org/C77281830 |
| concepts[6].level | 2 |
| concepts[6].score | 0.39302656054496765 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q718608 |
| concepts[6].display_name | Dosage form |
| concepts[7].id | https://openalex.org/C136229726 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3913806974887848 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q327092 |
| concepts[7].display_name | Biomedical engineering |
| concepts[8].id | https://openalex.org/C181389837 |
| concepts[8].level | 2 |
| concepts[8].score | 0.3823535144329071 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q461809 |
| concepts[8].display_name | Bioavailability |
| concepts[9].id | https://openalex.org/C3019981671 |
| concepts[9].level | 2 |
| concepts[9].score | 0.379241406917572 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q5165929 |
| concepts[9].display_name | Immediate release |
| concepts[10].id | https://openalex.org/C3020134792 |
| concepts[10].level | 2 |
| concepts[10].score | 0.34926649928092957 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q79749 |
| concepts[10].display_name | Human plasma |
| concepts[11].id | https://openalex.org/C163588942 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3191147446632385 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q5165929 |
| concepts[11].display_name | Controlled release |
| concepts[12].id | https://openalex.org/C3020079912 |
| concepts[12].level | 2 |
| concepts[12].score | 0.31842029094696045 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q3918988 |
| concepts[12].display_name | Plasma concentration |
| concepts[13].id | https://openalex.org/C71924100 |
| concepts[13].level | 0 |
| concepts[13].score | 0.2916843891143799 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[13].display_name | Medicine |
| concepts[14].id | https://openalex.org/C192562407 |
| concepts[14].level | 0 |
| concepts[14].score | 0.29139697551727295 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q228736 |
| concepts[14].display_name | Materials science |
| concepts[15].id | https://openalex.org/C112705442 |
| concepts[15].level | 2 |
| concepts[15].score | 0.29045748710632324 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q323936 |
| concepts[15].display_name | Pharmacokinetics |
| concepts[16].id | https://openalex.org/C43617362 |
| concepts[16].level | 1 |
| concepts[16].score | 0.2812986373901367 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[16].display_name | Chromatography |
| concepts[17].id | https://openalex.org/C202751555 |
| concepts[17].level | 2 |
| concepts[17].score | 0.2743498980998993 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[17].display_name | In vitro |
| concepts[18].id | https://openalex.org/C521977710 |
| concepts[18].level | 2 |
| concepts[18].score | 0.25310036540031433 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q81163 |
| concepts[18].display_name | Polymer |
| keywords[0].id | https://openalex.org/keywords/captopril |
| keywords[0].score | 0.8102431297302246 |
| keywords[0].display_name | Captopril |
| keywords[1].id | https://openalex.org/keywords/dosing |
| keywords[1].score | 0.6100714802742004 |
| keywords[1].display_name | Dosing |
| keywords[2].id | https://openalex.org/keywords/drug |
| keywords[2].score | 0.5417826771736145 |
| keywords[2].display_name | Drug |
| keywords[3].id | https://openalex.org/keywords/matrix |
| keywords[3].score | 0.5275700688362122 |
| keywords[3].display_name | Matrix (chemical analysis) |
| keywords[4].id | https://openalex.org/keywords/dosage-form |
| keywords[4].score | 0.39302656054496765 |
| keywords[4].display_name | Dosage form |
| keywords[5].id | https://openalex.org/keywords/bioavailability |
| keywords[5].score | 0.3823535144329071 |
| keywords[5].display_name | Bioavailability |
| keywords[6].id | https://openalex.org/keywords/immediate-release |
| keywords[6].score | 0.379241406917572 |
| keywords[6].display_name | Immediate release |
| language | |
| locations[0].id | doi:10.5281/zenodo.17747600 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306400562 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| locations[0].source.host_organization | https://openalex.org/I67311998 |
| locations[0].source.host_organization_name | European Organization for Nuclear Research |
| locations[0].source.host_organization_lineage | https://openalex.org/I67311998 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | |
| locations[0].raw_type | article-journal |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | False |
| locations[0].is_published | |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.5281/zenodo.17747600 |
| indexed_in | datacite |
| authorships[0].author.id | |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Shilpa Gangurde*, Irshad Ahamad |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shilpa Gangurde*, Irshad Ahamad |
| authorships[0].is_corresponding | True |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.5281/zenodo.17747600 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-12-01T00:00:00 |
| display_name | Formulation and Evaluation of Sustained Release Matrix Tablet of Captopril |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-12-01T00:07:19.613710 |
| primary_topic.id | https://openalex.org/T10256 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.7788326144218445 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3003 |
| primary_topic.subfield.display_name | Pharmaceutical Science |
| primary_topic.display_name | Drug Solubulity and Delivery Systems |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.5281/zenodo.17747600 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306400562 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| best_oa_location.source.host_organization | https://openalex.org/I67311998 |
| best_oa_location.source.host_organization_name | European Organization for Nuclear Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I67311998 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | |
| best_oa_location.raw_type | article-journal |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.5281/zenodo.17747600 |
| primary_location.id | doi:10.5281/zenodo.17747600 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306400562 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| primary_location.source.host_organization | https://openalex.org/I67311998 |
| primary_location.source.host_organization_name | European Organization for Nuclear Research |
| primary_location.source.host_organization_lineage | https://openalex.org/I67311998 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | |
| primary_location.raw_type | article-journal |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | False |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.5281/zenodo.17747600 |
| publication_date | 2025-11-28 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 1, 64, 90 |
| abstract_inverted_index.It | 105 |
| abstract_inverted_index.an | 195 |
| abstract_inverted_index.as | 63, 115 |
| abstract_inverted_index.by | 71, 202 |
| abstract_inverted_index.in | 44, 147 |
| abstract_inverted_index.is | 7, 163 |
| abstract_inverted_index.of | 13, 23, 93, 98, 103, 169, 178, 192 |
| abstract_inverted_index.to | 35, 67, 165, 180 |
| abstract_inverted_index.up | 179 |
| abstract_inverted_index.K4M | 119 |
| abstract_inverted_index.The | 129 |
| abstract_inverted_index.and | 15, 27, 48, 74, 82, 96, 111, 120, 126, 139, 150, 160, 206 |
| abstract_inverted_index.for | 10, 198 |
| abstract_inverted_index.its | 19 |
| abstract_inverted_index.the | 11, 94, 167 |
| abstract_inverted_index.wet | 140 |
| abstract_inverted_index.(SR) | 58 |
| abstract_inverted_index.934, | 123 |
| abstract_inverted_index.This | 40, 86 |
| abstract_inverted_index.drug | 50, 76, 170 |
| abstract_inverted_index.have | 61 |
| abstract_inverted_index.like | 136 |
| abstract_inverted_index.poor | 45 |
| abstract_inverted_index.such | 114 |
| abstract_inverted_index.(ACE) | 5 |
| abstract_inverted_index.(HPMC | 118 |
| abstract_inverted_index.about | 24 |
| abstract_inverted_index.daily | 33 |
| abstract_inverted_index.ethyl | 124 |
| abstract_inverted_index.heart | 16 |
| abstract_inverted_index.hours | 26 |
| abstract_inverted_index.rapid | 28 |
| abstract_inverted_index.short | 20 |
| abstract_inverted_index.these | 69 |
| abstract_inverted_index.using | 156 |
| abstract_inverted_index.vitro | 148 |
| abstract_inverted_index.K15M), | 121 |
| abstract_inverted_index.direct | 137 |
| abstract_inverted_index.dosing | 42, 204 |
| abstract_inverted_index.enzyme | 4 |
| abstract_inverted_index.hours, | 182 |
| abstract_inverted_index.matrix | 59, 101, 190 |
| abstract_inverted_index.plasma | 38, 80 |
| abstract_inverted_index.potent | 2 |
| abstract_inverted_index.review | 87, 130 |
| abstract_inverted_index.sodium | 127 |
| abstract_inverted_index.steady | 79 |
| abstract_inverted_index.widely | 8 |
| abstract_inverted_index.1.5–2 | 25 |
| abstract_inverted_index.12–24 | 181 |
| abstract_inverted_index.account | 92 |
| abstract_inverted_index.article | 88 |
| abstract_inverted_index.details | 131 |
| abstract_inverted_index.emerged | 62 |
| abstract_inverted_index.kinetic | 152 |
| abstract_inverted_index.levels, | 51 |
| abstract_inverted_index.patient | 46, 84 |
| abstract_inverted_index.release | 57, 100, 151, 176, 189 |
| abstract_inverted_index.results | 43 |
| abstract_inverted_index.tablets | 60, 102, 191 |
| abstract_inverted_index.therapy | 201 |
| abstract_inverted_index.Carbopol | 122 |
| abstract_inverted_index.Higuchi, | 159 |
| abstract_inverted_index.However, | 18 |
| abstract_inverted_index.Overall, | 187 |
| abstract_inverted_index.approach | 66 |
| abstract_inverted_index.extended | 175 |
| abstract_inverted_index.failure. | 17 |
| abstract_inverted_index.frequent | 41 |
| abstract_inverted_index.maintain | 36 |
| abstract_inverted_index.modeling | 155 |
| abstract_inverted_index.multiple | 32 |
| abstract_inverted_index.overcome | 68 |
| abstract_inverted_index.polymers | 113 |
| abstract_inverted_index.profiles | 177 |
| abstract_inverted_index.provides | 89 |
| abstract_inverted_index.reducing | 53, 203 |
| abstract_inverted_index.release, | 77 |
| abstract_inverted_index.release. | 171 |
| abstract_inverted_index.strategy | 197 |
| abstract_inverted_index.studies, | 133 |
| abstract_inverted_index.studies. | 153 |
| abstract_inverted_index.systemic | 29 |
| abstract_inverted_index.Captopril | 193 |
| abstract_inverted_index.Optimized | 172 |
| abstract_inverted_index.Sustained | 56 |
| abstract_inverted_index.adherence | 47 |
| abstract_inverted_index.alginate. | 128 |
| abstract_inverted_index.clearance | 30 |
| abstract_inverted_index.discussed | 164 |
| abstract_inverted_index.effective | 196 |
| abstract_inverted_index.elucidate | 166 |
| abstract_inverted_index.employing | 109 |
| abstract_inverted_index.enhancing | 199 |
| abstract_inverted_index.equations | 162 |
| abstract_inverted_index.following | 183 |
| abstract_inverted_index.frequency | 205 |
| abstract_inverted_index.half-life | 22 |
| abstract_inverted_index.improving | 83, 207 |
| abstract_inverted_index.including | 144 |
| abstract_inverted_index.kinetics. | 186 |
| abstract_inverted_index.mechanism | 168 |
| abstract_inverted_index.prolonged | 75 |
| abstract_inverted_index.promising | 65 |
| abstract_inverted_index.providing | 72 |
| abstract_inverted_index.represent | 194 |
| abstract_inverted_index.sustained | 99, 188 |
| abstract_inverted_index.Captopril, | 0 |
| abstract_inverted_index.Captopril. | 104 |
| abstract_inverted_index.biological | 21 |
| abstract_inverted_index.cellulose, | 125 |
| abstract_inverted_index.controlled | 73 |
| abstract_inverted_index.emphasizes | 106 |
| abstract_inverted_index.evaluation | 97, 142 |
| abstract_inverted_index.inhibitor, | 6 |
| abstract_inverted_index.management | 12 |
| abstract_inverted_index.parameters | 143 |
| abstract_inverted_index.prescribed | 9 |
| abstract_inverted_index.strategies | 108 |
| abstract_inverted_index.techniques | 135 |
| abstract_inverted_index.ultimately | 52 |
| abstract_inverted_index.compliance. | 85 |
| abstract_inverted_index.compression | 138 |
| abstract_inverted_index.fluctuating | 49 |
| abstract_inverted_index.formulation | 95, 107, 134 |
| abstract_inverted_index.hydrophilic | 110 |
| abstract_inverted_index.hydrophobic | 112 |
| abstract_inverted_index.limitations | 70 |
| abstract_inverted_index.maintaining | 78 |
| abstract_inverted_index.necessitate | 31 |
| abstract_inverted_index.therapeutic | 37, 54 |
| abstract_inverted_index.zero-order, | 157 |
| abstract_inverted_index.Mathematical | 154 |
| abstract_inverted_index.demonstrated | 174 |
| abstract_inverted_index.dissolution, | 149 |
| abstract_inverted_index.first-order, | 158 |
| abstract_inverted_index.formulations | 173 |
| abstract_inverted_index.granulation, | 141 |
| abstract_inverted_index.hypertension | 14 |
| abstract_inverted_index.comprehensive | 91 |
| abstract_inverted_index.hydroxypropyl | 116 |
| abstract_inverted_index.predominantly | 184 |
| abstract_inverted_index.effectiveness. | 55 |
| abstract_inverted_index.preformulation | 132 |
| abstract_inverted_index.administrations | 34 |
| abstract_inverted_index.concentrations, | 81 |
| abstract_inverted_index.concentrations. | 39 |
| abstract_inverted_index.methylcellulose | 117 |
| abstract_inverted_index.physicochemical | 145 |
| abstract_inverted_index.antihypertensive | 200 |
| abstract_inverted_index.bioavailability. | 208 |
| abstract_inverted_index.characterization, | 146 |
| abstract_inverted_index.Korsmeyer–Peppas | 161 |
| abstract_inverted_index.diffusion-controlled | 185 |
| abstract_inverted_index.angiotensin-converting | 3 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 1 |
| citation_normalized_percentile.value | 0.71898455 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |